成人急性髓系白血病患者自体干细胞移植后复发接受异基因干细胞移植:EBMT急性白血病工作组537例患者回顾性分析
该回顾性分析纳入EBMT登记处537例自体移植后复发或第二次完全缓解的成人急性髓系白血病患者,异基因移植后3年无白血病生存率31.4%,总生存率39.5%,复发率34.6%,非复发死亡率33.7%。在第二次完全缓解移植、自体移植后较晚复发及未接受预处理全身照射的患者中生存更优。
要点
- 自体移植后复发的成人AML患者接受异基因移植,3年总生存率39.5%
- 第二次完全缓解期移植者复发风险低于复发期移植者(HR 1.76)
- 自体移植前接受全身照射者非复发死亡风险增高(HR 2.43)
核心结论
- 约三分之一的成人急性髓系白血病患者自体移植后复发可通过异基因移植挽救,自体移植后较晚复发、第二次完全缓解期移植及自体移植前未接受全身照射者无白血病生存和总生存更优。
研究设计与样本
- 欧洲血液与骨髓移植学会(EBMT)登记处回顾性分析,纳入537例自体干细胞移植后复发或第二次完全缓解的成人急性髓系白血病患者,接受异基因干细胞移植。
主要发现
- 异基因移植后3年无白血病生存率31.4%(95%CI 27.3-35.6),总生存率39.5%(95%CI 35.1-43.9),复发率34.6%(95%CI 30.4-38.8),非复发死亡率33.7%(95%CI 29.6-37.9)。
- 复发期移植者较第二次完全缓解期移植者复发率更高(HR 1.76,P=0.004),自体移植后较晚复发者复发风险降低(HR 0.97/月,P<10^-3),两者均转化为更好的无白血病生存和总生存。
- 无关供者移植者较同胞全合供者移植者复发率更低(HR 0.49,P<10^-3)。
- 自体移植前接受全身照射者非复发死亡风险增高(HR 2.43,P<10^-4),导致无白血病生存和总生存更差。
- 减低强度预处理与清髓性预处理异基因移植者的无白血病生存和总生存无差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with acute myeloid leukemia (AML) who relapse after autologous stem cell transplantation (ASCT) can be rescued by allogeneic SCT. We identified 537 adult patients with AML allografted in second complete remission (CR2) or first relapse after ASCT in the European Society for Blood and Marrow Transplantation (EBMT) registry. At 3 years post allograft, leukemia free survival (LFS) was 31.4% [95%CI 27.3-35.6], overall survival (OS) 39.5% [95%CI 35.1-43.9], relapse incidence (RI) 34.6% [95%CI 30.4-38.8], and nonrelapse mortality (NRM) 33.7% [95%CI 29.6-37.9]. RI was higher in patients transplanted in relapse in comparison to those transplanted in CR2 (HR 1.76, P = .004) and in patients who relapsed later after ASCT (HR 0.97 per month, P < 10-3 ), both translating into better LFS/ OS. Relapse was also lower in patients undergoing allogeneic stem cell transplantation (allo-HSCT) from an unrelated donor (UD) in comparison to those transplanted from a matched sibling donor (MSD) (HR 0.49, P < 10-3 ). NRM was increased in patients who received total body irradiation (TBI) pre-ASCT (HR 2.43; P < 10-4), translating into worse LFS/OS. LFS/OS did not differ between patients allotransplanted with reduced intensity (RIC) or myeloablative (MAC) conditioning. In conclusion, one third of adult patients with AML relapsing post ASCT can be rescued with allo-HSCT, with better LFS/OS in patients who relapsed later post ASCT, those transplanted in CR2 and those who had not received TBI pre-ASCT.
引用
- Christopeit M, Labopin M, Gorin NC, et al. Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT. Am J Hematol. 2018. PMID: 30218444. doi:10.1002/ajh.25285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。